This continuing education program is
designed to provide clinicians with a review of the current cardiovascular
outcome trials (CVOTs) for antihyperglycemic agents. The goal is to ensure
clinicians have the most current data to ensure their patients are optimally
protected from major adverse cardiovascular events (MACE).
Expert Narratives in Cardiovascular Disease and Antihyperglycemic Therapy
CAN-eng
$0
free
Mainpro+
1 hour
Endocrinology
1 Credits
Course Description
Course Details
Expiry Date: 2021-10-01
Professions: Physician
Faculty
- Alice Y. Y. Cheng, MD, FRCPC
- James Kim, MBBch
- Jeff Habert, MD, CCFP, FCFP
- John Axler, MD, CCFP, FCFP
- Pierre Filteau, MD
Accreditation
This Self-Learning program has been certified by the College of Family Physicians of Canada for up to 1.0 Mainpro+ Credit.
Learning Objective(s)
Upon completion of this continuing education program clinicians will be better able to:
- Discuss the practical application of screening patients with T2DM for cardiovascular and renal risk factors
- Describe how the patient populations in the antihyperglycemic cardiovascular outcome trials differ from one another and the clinical significance of these differences
- Review key considerations in the antihyperglycemic agent selection in patients with established cardiovascular disease, renal disease or multiple cardiovascular risk factors
- Develop a cardioprotective treatment plan for patients with type 2 diabetes and one of the following:
- Established cardiovascular disease
- Renal disease
- Multiple cardiovascular risk factors